Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Madrigal Pharmaceuticals, Inc. (MDGL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical company focused on MASH, Madrigal uses SEC reports to present detailed information on its financial performance, capital structure, risk factors, and material corporate events related to Rezdiffra (resmetirom) and its broader pipeline.
Investors can review current reports on Form 8-K where Madrigal announces quarterly and annual financial results, material financing arrangements, licensing agreements, and other significant events. Recent 8-K filings describe quarterly earnings releases, a senior secured credit facility with funds managed by Blue Owl Capital, and the use of proceeds to repay and terminate a prior loan agreement, as well as shareholder voting results from the annual meeting.
In addition to 8-Ks, users can access Madrigal’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) to study revenue from Rezdiffra, research and development spending on the MAESTRO clinical program and pipeline assets such as the licensed oral GLP-1 receptor agonist and ervogastat, and detailed risk factor disclosures. These filings also discuss regulatory considerations around MASH indications, ongoing Phase 3 outcomes trials, and forward-looking statements about the company’s strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from long filings, helping readers quickly understand changes in liquidity, debt covenants, operating expenses, and other important metrics without reading every page. Users can also track executive and director-related disclosures when Forms 3, 4, and 5 appear in the SEC stream, providing visibility into equity awards and other reportable transactions.
By combining real-time EDGAR updates with AI-generated insights, this page offers a practical way to follow how Madrigal’s clinical progress in MASH, commercialization of Rezdiffra, and financing decisions are reflected in its official SEC reporting.
Madrigal Pharmaceuticals submitted Rule 144 notices reporting proposed and recent sales of Common Stock by insiders. The filing lists multiple historical sales, including 18,650 shares sold by Rebecca A. Taub on 01/09/2026 and 24,800 shares sold by Paul A. Friedman on 01/09/2026 The excerpt also shows a restricted stock unit vesting of 491 shares on 03/06/2026.
Madrigal Pharmaceuticals Chief Medical Officer David Soergel received new equity awards in the form of stock options and restricted stock units. On March 4, 2026, he was granted options for 5,467 shares at an exercise price of $0.00 per share and 4,374 shares of common stock as a restricted stock unit award.
The restricted stock units vest in four equal installments of 25% on March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, if he remains in service on each date. The option vests 25% on March 4, 2027, with an additional 6.25% vesting on the last day of each successive three‑month period, also subject to continued service. Following these grants, he directly holds 11,919 shares of common stock.
MDGL notice of proposed sale of 1,336 restricted stock units (RSUs) by an issuer-affiliated broker-dealer. The filing lists a trade date of 03/01/2026 and a prior sale of 1,183 common shares on 03/02/2026 reporting proceeds of $505,389.43.
Madrigal Pharmaceuticals EVP and CFO Mardi Dier had 1,183 shares of common stock sold at an average price of $427.21 per share. The shares were sold by the company on her behalf solely to cover tax withholding on vested restricted stock units, in an automatic, non-discretionary transaction. After this sale, she continues to hold 9,257 shares directly.
Madrigal Pharmaceuticals filed a Form 144 disclosing the proposed sale of 1,183 shares of Common Stock in connection with a Restricted Stock Unit grant that vested on 03/02/2026. The filing also reports a prior sale by a 10b5-1 plan of 4,173 shares on 12/02/2025 for $2,413,416.57.
Madrigal Pharmaceuticals director Richard S. Levy exercised stock options for 2,500 shares of common stock. The derivative transaction converted a fully vested stock option into 2,500 common shares at a price of $7.36 per share. Following this exercise, Levy directly owns 27,697 shares of Madrigal common stock.
Madrigal Pharmaceuticals is building a focused liver-disease franchise around Rezdiffra, its once-daily oral therapy for MASH with moderate to advanced fibrosis. Rezdiffra became the first approved treatment for this condition in the United States in March 2024 and received conditional marketing authorization in the European Union in August 2025, with launch in Germany that September.
For the year ended December 31, 2025, Madrigal generated $958.4 million in product revenue from Rezdiffra, with quarterly sales annualizing above $1.0 billion by year-end. The company is running long-term MAESTRO-NASH and MAESTRO-NASH OUTCOMES Phase 3 trials to convert accelerated approvals into full approvals and to expand into compensated cirrhosis, with key data expected in 2027 and 2028.
Madrigal is also using business development to build a combination-focused MASH pipeline. It entered a $500.0 million senior secured credit facility in July 2025, licensed oral GLP‑1 agonist MGL‑2086 from CSPC, Phase 2 DGAT‑2 inhibitor ervogastat from Pfizer, and six siRNA programs from Ribocure. As of February 12, 2026, the company had 22,939,969 common shares outstanding and a non‑affiliate equity value of about $5.6 billion as of June 30, 2025.
Madrigal Pharmaceuticals reported a breakout 2025, driven by its MASH drug Rezdiffra. Net revenues reached $321.1 million in the fourth quarter and $958.4 million for the full year, up sharply from $180.1 million a year earlier, with more than 36,250 patients on therapy by year-end.
Operating expenses also climbed, totaling $380.7 million in the quarter and $1,258.5 million for the year, reflecting heavy investment in commercialization and pipeline expansion. Madrigal ended 2025 with $988.6 million in cash and marketable securities and access to a senior secured credit facility of up to $500 million.
The company strengthened its long-term position with an Orange Book–listed Rezdiffra patent providing protection into 2045 and built an “industry-leading” MASH pipeline, including more than 10 programs such as siRNA candidates, an oral GLP-1 (MGL-2086), and the DGAT‑2 inhibitor ervogastat. Ongoing and planned trials aim to extend Rezdiffra’s use, including in compensated MASH cirrhosis (F4c).
Paulson & Co. Inc. filed an amended ownership report showing discretionary control over 1,707,522 shares of Madrigal Pharmaceuticals, Inc. common stock, representing 7.5% of the class. This percentage is based on 22,711,420 shares outstanding as of October 30, 2025.
The shares are owned by Paulson’s investment advisory clients, and Paulson disclaims beneficial ownership. Paulson reports sole voting and dispositive power over these shares and certifies the holdings are for investment purposes, not to change or influence control of Madrigal.
Janus Henderson Group plc filed an amended Schedule 13G reporting passive ownership of Madrigal Pharmaceuticals common stock. Through its investment adviser subsidiaries managing various client accounts, it may be deemed to beneficially own 1,584,843 shares, representing 7.0% of Madrigal’s common stock as of 12/31/2025.
The asset manager entities hold shared voting and shared dispositive power over these shares, while having no sole voting or dispositive power. Dividends and sale proceeds belong to the underlying managed portfolios, and Janus Henderson certifies the holdings are in the ordinary course of business and not for influencing control.